COMP <GO>
GRAL vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
GRAIL Inc. Common Stock (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: GRAL 4
— ABBV 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $143.43 (-9.75%) • MKT CAP: $7.10B
roic
-18.00%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GRAL VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GRAL | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -18.00% | 29.00% | -47.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.23% | 3.47% | -7.70 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 17.20% | 8.60% | +8.60 | GRAL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.26 | 5.33 | +1.93 | GRAL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.40% | -0.50 | GRAL | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.1 | 72.8 | -15.70 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.15 | -0.15 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 113.1x | -91.10 | GRAL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.10B | $513.86B | -$506.76B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GRAL REV | ABBV REV | GRAL GROSS % | ABBV GROSS % | GRAL FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $147.2M | $61.16B | 44.0% | 70.2% | -$299.9M | $17.82B |
| FY 2024 | $125.6M | $56.33B | 44.0% | 70.0% | -$582.4M | $17.83B |
| FY 2023 | $93.1M | $54.32B | 44.0% | 44.0% | -$600.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GRAL // BETA 1.00
ABBV // BETA 1.15